Table 2.
Indicators of disease progression and host response in A/Ncr and C57BL/6 mice infected with ECTV via the IN, SC or FP route1.
| Marker | Route | A/Ncr | C57BL/6 |
|---|---|---|---|
| Disease Progression | |||
| Day of death | IN | 7–8 (1000 PFU); 7–12 (20 PFU) | 9–14 (1000 PFU); |
| FP | 7–8 (1000 PFU) | N/A | |
| Weight change | IN | Lose weight from day 5 (5–1000 PFU | Lose weight from day 7 (1000 PFU) |
| FP | Lose weight from day 5 (1000 PFU) | N/A | |
| Infectivity titres | IN | Day 2 spleen, liver and lung (1000 PFU) | Day 3 liver; day 4 spleen and lung (1000 PFU) |
| FP | Day 2 spleen; day 4 liver; and day 6 lung (1000 PFU) | N/A | |
| ALT/AST | IN | Day 6 (1500 PFU) | >Day 7 (1500 PFU); day 5 (1x106 PFU) |
| Blood viral DNA | IN | Day 6 (5 PFU) | Day 4 (6500 PFU) |
| FP | Day 5 (1000 PFU) | - | |
| Host Response | |||
| IFN-γ | IN | Day 4 (20 PFU) | Day 4 (1×106 PFU) |
| SC | - | Day 2 (1×106PFU) | |
| Neutrophilia | IN | By day 8 (20 PFU) | By day 6 (1×106PFU) |
| PLN IFN-γ | FP | Day 2 (1000 PFU) | Day 1 (1000 PFU) |
| PLN Rantes | FP | No change (1000 PFU) | Day 1 (1000 PFU) |
| PLN IL-9 | FP | Day 1 (1000 PFU) | No change (1000 PFU) |
| PLN gene regulation | FP | 22 gene changes from 6–24 hours p.i. (1000 PFU) | 80 gene changes from 6–24 hours p.i. (1000 PFU) |
| Antigen presentation | IN | MLN no presentation up to day 3 (1×106 PFU) | MLN no presentation up to day 3 (1×106 PFU) |
| FP | PLN no presentation up to day 3 (1×106 PFU) | PLN presentation from day 1 (1×106 PFU) | |
| Spleen mass | IN | No change | Doubled from day 4–7 |
| FP | No change | Trebled from day 4–7 | |
| CD4 splenic intracellular IFN-γ | FP | 2×105 IFN-γ + cells by day 8 (3000 PFU attenuated virus EV-138) | 5×104 IFN-γ + cells by day 6 (3000 PFU attenuated virus EV-138) |
| CD8 splenic intracellular IFN-γ | FP | 2.5×105 IFN-γ + cells by day 8 (3000 PFU attenuated virus EV-138) | 2.5×106 IFN-γ+ cells by day 6 (3000 PFU attenuated virus EV-138) |
| Antibody | FP | N/A (1000 PFU) | Seroconversion by day 21 |